PharmiWeb.com - Global Pharma News & Resources
30-Sep-2021

LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials

LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials

29.9.2021 14:00:00 | LEO Pharma

Connected solution aims to deliver faster trials and a better patient experience BALLERUP, DENMARK and PLEASANTON, CA — Sept. 29, 2021 — LEO Pharma, a global leader in medical dermatology, and Veeva Systems (NYSE: VEEV) today announced a strategic technology partnership to enable scalable digital trials that are patient-centric and paperless.

Building on its success with the Veeva Clinical Operations Suite, LEO Pharma will complete its standardization on existing Veeva clinical technology, be an early adopter of future Veeva solutions, and help to shape the Veeva digital trials roadmap. By adopting technology and optimized business processes, LEO Pharma plans to achieve the following while maintaining the highest standards of data accuracy, regulatory compliance, and patient safety:

  • Significantly improved patient experience
  • Increased patient diversity through decentralized trials
  • Higher accuracy in clinical data
  • 25% reduction in clinical trial cost
  • 25% reduction in clinical trial time

LEO Pharma will utilize the integrated suite of Veeva clinical products, including eTMF, CTMS, CDMS, Site Connect, eConsent, ePRO, Virtual Visits, and eSource.

“We’ve been exploring ways to transform clinical trials, but COVID-19 sped up this process. By promptly responding to changing market dynamics, we kept our trials going without delay. Partnering with Veeva supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business,” said Jörg Möller, executive vice president and head of R&D at LEO Pharma. “Veeva’s track record of product excellence makes it the ideal long-term partner to help us achieve this, enabling us to help patients faster and better.”

“We’re thrilled and honored to extend our longstanding partnership with LEO Pharma to be an early adopter of our full digital trials platform,” said Peter Gassner, founder and CEO of Veeva. “We intend to help move the industry forward with a scalable digital trials platform that significantly improves the clinical trial process for patients, sites, and sponsors.”

Contacts

 

 

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

Henrik Heskjaer
LEO Pharma
+45 3140 6180
hdtdk@leo-pharma.com

Editor Details

Last Updated: 30-Sep-2021